The purpose of this study is to determine whether pharmacogenomic study of bioamine transporters and peripheral lymphatic biomarkers(phenotype) predict antidepressant responsiveness in advance before the appearance of the drug effects until 4\~6 weeks after drug administration.
The purpose of this study is to determine whether genomic effects or peripheral lymphatic biomarkers on antidepressant response differed by class of drug, whether genomic and biomarker differences between drug responders and nonresponders predict the response of antidepressant and to construct the prediction model for antidepressant treatment in order to aid to select the their genetically or endophenotypic matching drugs.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
1,000
Antidepressants administration for 6 weeks under therapeutic dose
Antidepressants administration for 6 weeks under therapeutic dose
Samsung Medical Center
Kangnam, Seoul, South Korea
Antidepressant Response at 6 weeks
antidepressant response is defined as the decrease rate of HAM-D score for 6week was = or \> 50% Measurement Unit = responders, nonresponders
Time frame: 6 weeks
Biological value at 0 and 6 weeks
Biological value is defined as 1. Genetic information of bioamine transporter genes of patients. Measurement unit = if it is SNP,it is A, T, G, or C, and if VNTR, short or long allele or 2. Biological measure value of patients at 0 and 6week after antidepressant treatment(ex. peripheral markers such as serum BDNF, CREB...). Measurement unit = numerical value and thier unit such as O.D.(Optical Density)
Time frame: 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.